Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prostate vs. colorectal screening

This article was originally published in The Gray Sheet

Executive Summary

75% of U.S. men aged 50 and older have had a prostate-specific antigen (PSA) test to screen for prostate cancer but only 63% have received any colorectal cancer screening test, according to Brenda Sirovich, MD, VA Outcomes Group, White Junction, Vt., et al. Reporting in the March 19 issue of the Journal of the American Medical Association, the authors conclude that men may be "more accepting" of a blood test for PSA than more invasive colorectal cancer tests. Physicians "should ensure that men who choose to be screened for cancer are aware of the known mortality benefit of colorectal cancer screening and the uncertain benefits of screening for prostate cancer"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT018094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel